A New Era Of Medicine | The Brainstorm EP 114

Key Concepts

• Xvivo Gene Editing: Editing cells outside the body, requiring cell collection, manipulation, and re-infusion. (e.g., Casgevy for sickle cell disease)
• Invivo Gene Editing: Editing cells directly within the body, utilizing delivery systems like lipid nanoparticles.
• Lipid Nanoparticle (LNP) Delivery: A method of delivering gene editing components to target cells using fatty bubbles.
• APOL3 Gene: A gene linked to cardiovascular disease risk; loss-of-function variants offer protection.
• Value-Based Pricing: Determining the price of a treatment based on the health benefits it provides.
• Monte Carlo Simulation: A computational technique using random sampling to model potential outcomes.
• Total Addressable Market (TAM): The total market demand for a product or service.
• Quality-Adjusted Life Year (QALY): A measure of health outcome that combines both the quantity and quality of life.

Gene Editing Transition & Cardiovascular Disease: A Deep Dive

Introduction & The Shift from Xvivo to Invivo

The discussion centers on a significant transition in gene editing: moving from Xvivo (outside the body) to Invivo (inside the body) editing. This shift is driven by advancements in lipid nanoparticle (LNP) delivery technology. The initial success of Casgevy, the first CRISPR-based therapy approved by the FDA for sickle cell disease, demonstrated the potential of gene editing but highlighted the complexities of the Xvivo approach. Casgevy’s treatment journey involves a year-long process of cell collection, editing, patient conditioning (similar to bone marrow transplant preparation), infusion, and recovery. This complexity introduces significant operational and commercial friction. Invivo editing, using LNPs to deliver editing components directly to cells within the liver, promises a dramatically simplified treatment pathway – potentially a single outpatient infusion.

The Cardiovascular Disease Case Study

Cardiovascular disease (CVD), the leading cause of death globally, serves as a compelling case study for the benefits of Invivo gene editing. The accumulation of lipids (cholesterol, triglycerides) in artery walls leads to increased heart attack risk. While statins have been used for decades to inhibit cholesterol synthesis (reducing risk by ~29%), patient adherence is poor due to side effects and the preventative nature of the treatment. Interestingly, individuals born with a loss-of-function variant in the APOL3 gene exhibit lower lipid levels and a 30-40% reduction in coronary artery disease risk without apparent negative health consequences. Invivo gene editing aims to replicate this protective profile through a one-time intervention.

Editing Efficiency & Risk Reduction

Pre-clinical data demonstrates that Invivo LNP-delivered CRISPR can achieve up to 70% editing efficiency in non-human primates. Using the natural example of individuals with the APOL3 variant (50% editing efficiency correlating to a 41% reduction in coronary artery disease risk), modeling suggests that 70% editing efficiency could translate to a potential 52% reduction in coronary artery disease risk. This is based on the premise that gene editing isn’t perfect, and not every cell will be successfully edited.

Commercial Opportunity & Value-Based Pricing

The potential market for Invivo gene editing for CVD is substantial. Approximately 26 million Americans have atherosclerotic cardiovascular disease, and two-thirds of those patients fail to reach guideline-recommended lipid levels. A value-based pricing model, considering the health benefits provided, estimates a price of $165,000 per treatment. Applying this price to the 17 million potential early adopters (those with existing plaque buildup and uncontrolled lipid levels) yields a total addressable market (TAM) of $2.8 trillion. This dwarfs the $250 billion in cumulative sales achieved by Lipitor, a blockbuster statin, suggesting that even capturing a small fraction of the TAM could result in significant commercial success.

The discussion highlights a potential shift in treatment paradigms: moving from preventative measures with limited adherence (statins) to a one-time intervention offering durable risk reduction. The current healthcare system often prioritizes treatment of acute conditions rather than preventative measures, creating a challenge for widespread adoption of Invivo gene editing for primary prevention. However, the potential for out-of-pocket payment by affluent individuals seeking longevity could accelerate data collection and demonstrate the treatment’s efficacy.

Timeline for Commercial Rollout

The current stage is early Phase 1 clinical trials. Based on current data showing up to 80% reduction in lipid biomarkers, the next step is to demonstrate a reduction in adverse events (heart attacks) in a larger patient population. A commercial rollout is realistically projected for the early next decade, contingent on successful clinical trials and regulatory approval.

Additional Points & Considerations

• Externalities & Cost Savings: The value-based price considers not only the direct health benefits but also the potential cost savings from avoiding future cardiovascular events (hospitalizations, surgeries).
• Comparison to GLP-1 Drugs: The discussion draws parallels to the price decline observed with GLP-1 drugs, suggesting that the price of Invivo gene editing may also decrease over time as the technology matures and competition increases.
• The Role of Innovation & Risk: The investment in space-based data centers is framed as a strategic move to secure a competitive advantage, even if the immediate economic returns are uncertain. The ability to rapidly deploy new technologies is seen as crucial.
• Ethical Considerations: The discussion touches on the ethical implications of extending lifespan and the potential for disparities in access to these advanced therapies.

Conclusion

The transition from Xvivo to Invivo gene editing, particularly exemplified by the potential application to cardiovascular disease, represents a paradigm shift in medicine. While challenges remain in terms of clinical development, regulatory approval, and commercialization, the potential benefits – a simplified treatment pathway, durable risk reduction, and a massive addressable market – are compelling. The success of this approach could not only transform the treatment of rare diseases but also address some of the most prevalent and deadly conditions worldwide.